Evidence map›Paper›PMID 39871565›Full record

ArticleCurrent pharmaceutical design2025

Mesenchymal Stem Cell-conditioned Medium Attenuated CoCl

Yiping Liu, Yongda Lin, Ziqiang Wang, Wenzhuang Tang, Chunling Liao, Tianbiao Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yiping LiuDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Yongda LinDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Ziqiang WangDepartment of Nephrology, the First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Wenzhuang TangDepartment of Nephrology, the First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
Chunling LiaoDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Tianbiao ZhouDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.

Funding

Hainan Province Science and Technology Special Fund ZDYF2021SHFZ081
6 · The paper itself

Abstract

backgroundsRenal interstitial fibrosis (RIF) constitutes the ultimate pathological alteration in nearly all chronic kidney diseases (CKD). Mesenchymal stem cell conditioned medium (MSC-CM) exhibits an alleviating impact on renal fibrosis. However, the underlying mechanism remains unclear. The objective of this study was to explore whether MSC-CM regulates the expression of α-smooth muscle actin (α-SMA), Transforming growth factor-β1 (TGF-β1), Hypoxia-inducible factor-1α (HIF-1α), Nuclear receptor coactivators (NCOA1), and SRY-related high mobility (Sox9).

methodsRat renal tubular epithelial cells (RTECs), NRK-52E, were treated with diverse concentrations of Cobalt chloride (CoCl

resultThe microscopic findings demonstrated that MSC-CM was able to decrease the degree of cytochemical hypoxia damage in NRK-52E cells induced by CoCl

conclusionOur findings indicate that MSC-CM exerts a protective effect on RTECs by down-regulating α-SMA, TGF-β1, HIF-1α, NCOA1, and Sox9.

Indexed as

CobaltEpithelial CellsHypoxia-Inducible Factor 1, alpha SubunitKidney TubulesMesenchymal Stem CellsNuclear Receptor Coactivator 1SOX9 Transcription FactorAnimalsCell LineCells, CulturedCulture Media, ConditionedRatsCobaltcobaltous chlorideCulture Media, ConditionedHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitNuclear Receptor Coactivator 1Sox9 protein, ratSOX9 Transcription FactorHIF-1αMSC-CMNCOA1RIFRTECsSox9.

Identifiers

PMID39871565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.